TrialBlood2016

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

Jakub Krejcik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.